Home Coronavirus Natural Immunity to Covid-19 does not Wane

Natural Immunity to Covid-19 does not Wane

by Paul Ebeling

#Covid #immunity #natural #vaccine

“So, something unusual is occurring in the case of vaccine immunity, lets see…”–Paul Ebeling

A new scientific study has found that natural immunity to Covid-19 does not wane by even 1%, but real-world data unfortunately shows the same can not be said for vaccine acquired immunity.

something unusual is occurring in the case of vaccine immunity.

Big Pharm companies are not going to fund research into the benefits of natural immunity. Neither are health departments or politicians who act as if they are owned by those same drug companies. But if you have an oil well in your back garden things are rather different.

So the Qataris have done the necessary research in a new published study that can be viewed here.

Nearly 90% of Qatar’s population are expatriates from over 150 countries. Data was taken from the Qatari National digital-health information platform, which is nationally comprehensive containing all relevant Qatari data. This was not a sample of data. It was all of it. Here are the stated results of the paper…

Effectiveness of pre-Omicron primary infection against pre-Omicron reinfection was 85.5% (95% CI: 84.8-86.2%). Effectiveness peaked at 90.5% (95% CI: 88.4-92.3%) in the 7th month after the primary infection, but waned to ∼70% by the 16th month. Extrapolating this waning trend using a Gompertz curve suggested an effectiveness of 50% in the 22nd month and <10% by the 32nd month.

Effectiveness of pre-Omicron primary infection against Omicron reinfection was 38.1% (95% CI: 36.3-39.8%) and declined with time since primary infection.

A Gompertz curve suggested an effectiveness of <10% by the 15th month. Effectiveness of primary infection against severe, critical, or fatal COVID-19 reinfection was 97.3% (95% CI: 94.9- 98.6%), irrespective of the variant of primary infection or reinfection, and with no evidence for waning. Similar results were found in sub-group analyses for those ≥50 years of age.d

The tabulated findings together with a further Qatari paper, can be found here, on the waning of vaccine efficiency for comparison

https://www.nejm.org/doi/full/10.1056/nejmoa2114114  A study in Qatar into the effectiveness of the Pfizer mRNA jab

So natural immunity provides non waning 97.3% long term protection against severe, critical or fatal infection for at least 14 months and by extrapolation – indefinitely. Whereas mRNA vaccine immunity wanes to 55.6% at some time after 7 months. The Expose has repeatedly shown from UK figures that vaccinated people are more likely to die than unvaccinated people from Covid and we know that almost all unvaccinated people now have natural immunity. There is actually a Qatari paper which reluctantly reaches the same conclusion.

https://www.nature.com/articles/s41467-022-30895-3 Pfizer and Moderna “Vaccine effectiveness (against infection in Qatar) reached small but statistically significant negative values at 7 months or more after the second dose”.

So, these figures are flattering to the vaccines which are deliberately not investigated much after 6 months. But the key takeaway is that natural immunity does not wane at all in its capacity to save your life. Not by one percent and not in 14 months. So something unusual is occurring in the case of vaccine immunity. One can also see this from the latest worldwide cases and deaths and booster stats…

SADS (Sudden Adult Death Syndrome) is a term used internationally for deaths for which the post-mortem does not reveal any obvious cause of death. In other words, it is a new cause of death resulting from a new phenomenon which applies worldwide

Have a prosperous day, Keep the Faith!

#Covid, #immunity, #natural , #vaccine,

You may also like


Your Trusted Source for Capital Markets & Related News

© 2024 LiveTradingNews.com – For The Traders, By The Traders – All Right Reserved.

The information contained on this website shall not be construed as (i) an offer to purchase or sell, or the solicitation of an offer to purchase or sell, any securities or services, (ii) investment, legal, business or tax advice or an offer to provide such advice, or (iii) a basis for making any investment decision. An offering may only be made upon a qualified investor’s receipt not via this website of formal materials from the Knightsbridge an offering memorandum and subscription documentation (“offering materials”). In the case of any inconsistency between the information on this website and any such offering materials, the offering materials shall control. Securities shall not be offered or sold in any jurisdiction in which such offer or sale would be unlawful unless the requirements of the applicable laws of such jurisdiction have been satisfied. Any decision to invest in securities must be based solely upon the information set forth in the applicable offering materials, which should be read carefully by qualified investors prior to investing. An investment with Knightsbridge is not suitable or desirable for all investors; investors may lose all or a portion of the capital invested. Investors may be required to bear the financial risks of an investment for an indefinite period of time. Qualified investors are urged to consult with their own legal, financial and tax advisors before making any investment. Knightsbridge is a private investment firm that offers investment services to Qualified Investors, Members and Institutions ONLY. Qualified Investors are defined as individuals who have met those Qualifications in the relevant jurisdictions. Members are defined as individuals who have been accepted into the Knightsbridge membership program. Institutions are defined as entities such as banks, pension funds, and hedge funds. If you are not a Qualified Investor, Member or Institution, you are not eligible to invest with Knightsbridge. All investments involve risk, and there is no guarantee of profit. You may lose some or all of your investment. Past performance is not indicative of future results. Knightsbridge is not a registered investment advisor, and this disclaimer should not be construed as investment advice. Please consult with a qualified financial advisor before making any investment decisions. By accessing this website, you agree to the terms of this disclaimer. Thank you for your interest in Knightsbridge.